Correlation Between Citigroup and Can Fite

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Citigroup and Can Fite at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citigroup and Can Fite into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citigroup and Can Fite Biopharma, you can compare the effects of market volatilities on Citigroup and Can Fite and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citigroup with a short position of Can Fite. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citigroup and Can Fite.

Diversification Opportunities for Citigroup and Can Fite

0.54
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Citigroup and Can is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Citigroup and Can Fite Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Can Fite Biopharma and Citigroup is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citigroup are associated (or correlated) with Can Fite. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Can Fite Biopharma has no effect on the direction of Citigroup i.e., Citigroup and Can Fite go up and down completely randomly.

Pair Corralation between Citigroup and Can Fite

Taking into account the 90-day investment horizon Citigroup is expected to generate 0.55 times more return on investment than Can Fite. However, Citigroup is 1.83 times less risky than Can Fite. It trades about 0.08 of its potential returns per unit of risk. Can Fite Biopharma is currently generating about -0.13 per unit of risk. If you would invest  6,095  in Citigroup on January 25, 2024 and sell it today you would earn a total of  153.00  from holding Citigroup or generate 2.51% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy77.27%
ValuesDaily Returns

Citigroup  vs.  Can Fite Biopharma

 Performance 
       Timeline  
Citigroup 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Citigroup are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating fundamental indicators, Citigroup exhibited solid returns over the last few months and may actually be approaching a breakup point.
Can Fite Biopharma 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Can Fite Biopharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Can Fite is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Citigroup and Can Fite Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Citigroup and Can Fite

The main advantage of trading using opposite Citigroup and Can Fite positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citigroup position performs unexpectedly, Can Fite can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Can Fite will offset losses from the drop in Can Fite's long position.
The idea behind Citigroup and Can Fite Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Other Complementary Tools

Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stocks Directory
Find actively traded stocks across global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Fundamental Analysis
View fundamental data based on most recent published financial statements
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities